See related Commentary: <http://breast-cancer-research.com/content/5/6/329>

Introduction
============

Breast cancer remains a major cause of cancer death in women in the developed world. Novel therapeutic modalities are needed for those patients in whom chemotherapy, hormonal treatment and external radiation therapy are ineffective. 2-Deoxy-2-\[^18^F\]fluoro-D-glucose (^18^F-FDG) is widely used in positron emission tomography (PET) for the evaluation of patients with tumors \[[@B1],[@B2]\]. It was shown by Warburg in 1930 that glucose is actively utilized by tumor cells \[[@B3]\]. In recent years the use of ^18^F-FDG-PET has become well established in the diagnosis of breast cancer, because many breast cancers demonstrate high avidity for ^18^F-FDG \[[@B4]\], which is an analogue of glucose in which the hydroxy group in the 2 position has been replaced with a fluorine atom. ^18^F-FDG is taken up by the cells and phosphorylated by hexokinase to ^18^F-FDG-6-phosphate. Because ^18^F-FDG is not a substrate for glycolysis and does not undergo further metabolism, it remains trapped in the cell \[[@B5]\].

^18^F emits positrons with an average energy of 0.250 MeV and abundance of 96%. Positrons lose their kinetic energy in the tissue in the same manner as electrons, thereby damaging tissue. This is followed by annihilation, which results in the emission of two photons with an energy of 511 keV in opposite directions. Although the potential of electrons to kill cancer cells through the loss of their kinetic energy has been made use of in radionuclide cancer treatment for more than 50 years (since the introduction of therapy of thyroid cancer with ^131^I \[[@B6]\]), the therapeutic potential of positrons has remained unexplored. Theoretically, positrons should kill cancer cells during the loss of kinetic energy in the same manner as electrons.

Here we evaluate, for the first time to our knowledge, the potential of ^18^F-FDG as a positron-emitting agent for the radiomolecular therapy of breast cancer in breast cancer animal models and, retrospectively, in patients with metastatic breast cancer.

Materials and methods
=====================

Animals
-------

All procedures involving mice were conducted in accordance with the National Institutes of Health regulations concerning the use and care of experimental animals. The study of mice was approved by the Albert Einstein College of Medicine Animal Use Committee. Transgenic mice expressing the polyoma middle T antigen (PyMT) in the mammary epithelium under the control of mouse mammary tumor virus (MMTV) long terminal repeat were provided by Dr WJ Muller (McMaster University, Ontario, Canada) and then bred in our institution. At the age of 10 weeks these mice have multiple mammary tumors 0.15--0.17 cm in diameter. In mice older than 18 weeks the tumors are more than 1 cm in diameter. MMTV-*Neu*T mice \[[@B7]\], which carry *erbB-2*(*Neu*), one of the better known human breast cancer oncogenes, were purchased from Jackson Laboratories. MMTV-*Neu*T mice were obtained as retired breeders and some of them developed mammary tumors at the age of 5 months, whereas others remained-tumor free until 6--7 months of age. C3H/B6 female mice lacking the PyMT transgene were used as healthy controls in therapy experiments.

Imaging of mice with ^18^F-FDG
------------------------------

PyMT mice older than 18 weeks, with tumors more than 1 cm in diameter, MMTV-*Neu*T tumor-bearing mice (0.5--1 cm in diameter) and tumor-free MMTV-*Neu*T mice were fasted for 4 hours before the injection of radiotracer. Three animals were used in each group. They were anesthetized with a mixture of 125 mg/kg ketamine and 10 mg/kg xylazine. An injection of 0.5--2.0 mCi ^18^F-FDG was administered intraperitoneally (i.p.). The mice rested while anesthetized for an uptake period of 1 hour. A scan was performed on a dedicated PET scanner CPET (Philips). Scans (6 min emission and 45 s transmission) were obtained. The data were acquired with a zoom of 2 and a slice thickness of 2 mm. Images were reconstructed with an iterative reconstruction algorithm and corrected for attenuation. To reduce volume averaging, a small round region of interest 12 pixels in size was drawn in the center of the tumor and in the center of normal liver. The diameter of the region was 7 mm. The tumor to liver ratios (TLRs) were calculated by the formula TLR = counts per pixel in tumor divided by counts per pixel in liver.

Radiotoxicity studies of ^18^F-FDG in healthy mice
--------------------------------------------------

After a 4-hour fast, 2 groups of BALB/c mice were treated i.p. with the following doses of ^18^F-FDG: group 1 (three mice), 2.5 mCi; group 2 (three mice), 5 mCi; group 3 (three mice), left untreated for control. The mice were monitored for changes in behavior and body weight for 1 month, after which they were killed; their heart, brain, liver, kidneys, bladder, and bone marrow were removed, fixed in buffered formalin, sectioned, stained with hematoxylin and eosin (H&E), and analyzed histologically.

Treatment of PyMT mice with ^18^F-FDG
-------------------------------------

After a 4-hour fast, three groups of mice were treated i.p. with the following doses of ^18^F-FDG: group 1 (five 10-week-old mice), 2--4 mCi; group 2 (three 22-week-old mice), 2 mCi; group 3 (two C3H/B6 mice), 3 mCi to assess radiation damage to healthy breast tissue. Three 10-week-old and two 22-week-old PyMT mice served as untreated controls. At 10 days after treatment, mice were killed. In younger mice, the right abdominal mammary glands were removed for whole mount preparation as described \[[@B8]\], then fixed in buffered formalin and sectioned. In older mice, the tumors were removed and processed as above. Some sections were stained with H&E; others were analyzed for the presence of apoptotic and necrotic cells.

Apoptosis and necrosis detection
--------------------------------

The detection of apoptotic and necrotic cells in the tumors was performed with an Apoptag Plus^®^apoptosis detection kit (Serologicals) in accordance with the manufacturer\'s instructions. In brief, 3\'-OH termini of DNA fragments, which are the hallmark of apoptosis, were labeled with digoxigenin-modified nucleotides by terminal deoxynucleotidyl transferase. This enzyme selectively detects apoptotic over necrotic cells. The labeled DNA was detected with an anti-digoxigenin antibody, and detection was performed with a chromagen: apoptotic cells were stained brown, and areas of necrosis were stained yellow.

^18^F-FDG-PET in breast cancer patients with metastatic disease
---------------------------------------------------------------

Approval was obtained from the Albert Einstein College of Medicine Cancer Center Protocol Review Committee and the Montefiore Medical Center Institutional Review Board. Retrospectively, five consecutive patients with breast cancer and metastatic disease shown on ^18^F-FDG-PET scanning were evaluated. After more than 4 hours of fasting, the patients were administered 3.5 mCi of ^18^F-FDG, and rested during an uptake period of 45 min. The patients then underwent a whole-body scan on the CPET scanner. The scanning protocol consisted of 6 min of emission and two rotations of a ^137^Cs source for transmission per bed position, and approximately six bed positions. Images were corrected for attenuation and reconstructed with the iterative method. To reduce volume averaging, a small round region of interest 12 pixels in size was drawn in the center of the tumor and in the center of normal liver. The diameter of the region was 14 mm. Standardized uptake values (SUVs) were calculated for all regions of interest by the formula SUV = (activity in tissue \[mCi/g\]) divided by (injected activity \[mCi\]/body weight \[g\]).

TLRs were calculated by the formula TLR = SUV of tumor divided by SUV of liver.

The dose-limiting organ for therapy with ^18^F-FDG is the bone marrow. The activity of ^18^F-FDG that will deliver doses of 200 rad to the red marrow (less than 5% damage in 5 years) \[[@B9]\] and also 300 rad were calculated using the Medical Internal Radionuclide Dosimetry formalism. A dose of 300 rad was considered because it causes acceptable and manageable hematologic toxicity in selected patients \[[@B9]\]. The subsequent doses delivered to ^18^F-FDG-avid tumors were calculated.

Results
=======

Uptake of ^18^F-FDG in mammary tumors of PyMT and MMTV-*neuT*mice
-----------------------------------------------------------------

Coronal PET images of PyMT and MMTV-*neu*T mice injected with ^18^F-FDG are presented in Figure [1](#F1){ref-type="fig"}. Slices (2 mm thickness) with the highest activity in the tumor were chosen. There was significant uptake of ^18^F-FDG by the tumors in PyMT (Fig. [1a,1b](#F1){ref-type="fig"}) and MMTV-neuT mice (Fig. [1c](#F1){ref-type="fig"}). The tumor uptake was uniform. TLRs were (mean ± SD) 1.6 ± 0.4 and 1.6 ± 0.1 in MMTV-*neu*T and PyMT mice, respectively. No abnormal uptake was seen in a tumor-free mouse (Fig. [1d](#F1){ref-type="fig"}). As ^18^F-FDG is normally excreted in the urine, bladder activity was visible in all mice. The avidity of tumors for ^18^F-FDG provided an impetus for investigation of the therapeutic effect of ^18^F-FDG on mammary tumors in mice.

Lack of radiotoxicity of ^18^F-FDG in normal mice
-------------------------------------------------

Treatment of healthy mice with doses of up to 5 mCi ^18^F-FDG caused no damage in major organs (as determined by histological examination) including bone marrow, which is a dose-limiting organ in patients (results not shown).

Toleration of treatment of PyMT mice with ^18^F-FDG
---------------------------------------------------

PyMT mice treated with 2--4 mCi ^18^F-FDG were observed for 10 days for obvious signs of radiation toxicity. At 24 h after injection no radioactivity was detected in mice because of the excretion and complete radioactive decay of the relatively short-lived isotope ^18^F (half-life 110 min). No changes in eating and drinking habits, urine and fecal excretion, or body weight were seen.

Damage to the tumors by ^18^F-FDG
---------------------------------

Figure [2](#F2){ref-type="fig"} shows microscopic images of small and large tumors from PyMT mice. The small (0.15--0.17 cm diameter) tumors from 10-week-old mice treated with ^18^F-FDG had numerous apoptotic cells clearly present in the center of the treated tumors (Fig. [2a](#F2){ref-type="fig"}) that were not detected in untreated tumors (Fig. [2b](#F2){ref-type="fig"}). Overall, 4 ± 1% of cells in the treated small tumors were apoptotic, in comparison with less than 1% in untreated tumors (*P*\< 0.05). No apoptosis or necrosis was detected in the healthy mammary glands of C3H/B6 mice treated with 3 mCi of ^18^F-FDG (Fig. [2c](#F2){ref-type="fig"}). ^18^F-FDG treatment also caused much more cell death through the necrotic pathway in large (more than 1 cm) tumors in 22-week-old mice than occurred in untreated tumors (Fig. [2d,2e](#F2){ref-type="fig"}). In the treated tumors, the areas occupied by necrotic cells were stained brown--yellow (Fig. [2d](#F2){ref-type="fig"}), as opposed to the sheets of bluish tumor cells in untreated controls (Fig. [2e](#F2){ref-type="fig"}). Necrotic areas constituted 14% of the tumor volume in 22-week-old mice. Some apoptotic cells were also visible at the rim of the necrotic area.

Figure [2f,2g](#F2){ref-type="fig"} displays H&E-stained large tumors from 22-week-old PyMT mice. Tumors that had been treated with ^18^F-FDG were bloody when sectioned, which suggests resorption. This observation was confirmed by heavy infiltration of leukocytes in the H&E-stained section (Fig. [2f](#F2){ref-type="fig"}). Furthermore, the sections of the tumors treated with ^18^F-FDG showed a loss of coherence of the tumor cells with breaks in the epithelial sheets (Fig. [2f](#F2){ref-type="fig"}) as opposed to solid sheets of tumor cells found in the untreated controls (Fig. [2g](#F2){ref-type="fig"}).

^18^F-FDG-PET in breast cancer patients with metastatic disease
---------------------------------------------------------------

Table [1](#T1){ref-type="table"} summarizes the SUVs for metastatic tumors, SUVs for normal liver and TLRs in patients with metastatic breast cancer imaged with ^18^F-FDG. ^18^F-FDG-avid metastatic breast cancer in five retrospectively studied patients showed an average TLR of 2.7 ± 0.8. Figure [3](#F3){ref-type="fig"} presents a ^18^F-FDG-PET projection image of a patient with breast cancer, metastatic to the right lung. A left lung metastasis was also seen. Normal activity in the heart, liver, kidneys, bladder, and bowel was observed. It should be also noted that the primary breast cancer had previously been resected, and the residual normal non-lactating breast tissue did not display increased ^18^F-FDG uptake over the background. The SUV within a tumor was uniform, because our patients did not display areas of necrosis in the tumors. In patients with multiple tumors the SUVs varied from site to site. In patient 5, the most intense SUV was 9.9 in the tumor with a diameter of 5 cm, and the least intense SUV was 2.9 in the tumor with a diameter of 1.5 cm. In patient 3, the SUV was 5.8 in the tumor with dimensions 10 cm × 6 cm × 4.5 cm, and the lowest SUV was 3.8 in the tumor with a diameter of 2 cm.

The activity of ^18^F-FDG to deliver 200 rad to the red marrow was calculated to be 4.76 Ci for a 70 kg woman, and the subsequent tumor doses were calculated to be 220, 1100, and 2200 rad for SUVs of 1, 5, and 10, respectively. The activity of ^18^F-FDG to deliver 300 rad to the red marrow was calculated to be 7.14 Ci, and tumor doses would be 330, 1650, and 3300 rad for SUVs of 1, 5, and 10, respectively. These doses are in the tumoricidal range.

Discussion
==========

We have reported the use of positrons for the treatment of malignancy. Theoretically, these positrons can kill cancer cells in the same manner as electrons. However, the cytocidal potential of positrons remains largely unexplored. Historically, owing to the early success of the therapy of thyroid cancer with ^131^I, which emits electrons, much of the further development of radiopharmaceuticals for cancer therapy has concentrated on electron-emitting radioisotopes. The only reported use of the cytocidal potential of positrons was described by Stoll and colleagues \[[@B10]\], who used a balloon filled with the positron-emitter ^68^Ga for coronary artery brachytherapy to prevent restenosis.

Metabolic trapping of ^18^F-FDG is an attractive mechanism for delivering radioactivity to tumors, because neoplastic cells have an enhanced rate of glucose utilization \[[@B11]\]. This mechanism has been used successfully in ^18^F-FDG-PET, which is widely used in nuclear medicine for the diagnosis of oncological diseases. ^18^F-FDG has the ability to remain in cancer cells with low efflux rates. With a physical half-life of almost 2 hours, ^18^F emits energetic positrons with high abundance (96%) and a path length in tissue of about 0.1--0.2 cm. These qualities make ^18^F-FDG a potential candidate for investigation as an agent for the treatment of breast and other cancers.

Our imaging experiments in two different mouse mammary cancer models (the PyMT model of murine mammary cancer and the MMTV *Neu*T model, which carries the *erbB-2*human breast cancer oncogenes) showed that it is possible to use these models for the investigation *in vivo*of the tumoricidal properties of positrons, because tumor uptake was demonstrated. We observed apoptosis and necrosis in tumors treated with ^18^F-FDG; particulate ionizing radiation is known to cause cell death through both the apoptotic \[[@B12]\] and necrotic pathways \[[@B13],[@B14]\]. In small tumors (0.15--0.17 cm in diameter) in PyMT mice treated with ^18^F-FDG, the prevalent mode of cell death was apoptosis, whereas in large tumors (more than 1 cm in diameter) the radiation induced widespread necrosis. A possible explanation for this difference is that as the tumor diameter increased and there was an exponential increase of the absorbed radiation dose to the tumor, the high doses of radiation to the cell surface led to the focal stimulation of tumor necrosis factor-α expression \[[@B13]\] and a high influx of calcium \[[@B14]\], which induced necrosis instead of apoptosis. ^18^F-FDG at the 2--4 mCi doses that were used for the therapy of tumor-bearing animals contained 0.001--0.002 mg of unlabelled FDG, which should not cause any pharmacological effect because the level of glucose in the blood at fasting is 0.7 mg/ml (70 mg/dl).

A retrospective study of five patients with metastatic breast cancer imaged with ^18^F-FDG provided high SUVs in the tumors (2.7 ± 0.8). In patients with multiple tumors the SUVs varied from site to site. The tumors with greater uptake of the non-metabolite are affected more than the tumors with less uptake during positron therapy. The SUV of small tumors might suffer from volume averaging in measurement, and these tumors might actually receive a higher dose to the tumor than was measured. The dose-limiting organ for ^18^F-FDG administration is the red marrow. Other normal tissues show high ^18^F-FDG uptake, but they are relatively radioresistant. There are methods to reduce uptake by normal tissue. Uptake by cardiac and skeletal muscle is routinely reduced by fasting, and uptake by skeletal muscle can be further reduced with benzodiazepine therapy \[[@B15]\]. Uptake by brain is impossible to avoid. With an administered dose of 7.14 Ci of ^18^F-FDG, the dose to the brain is 570 rad. In external beam brain radiation therapy, 5040 rad is given in 28 fractions of 180 rad each, accompanied by corticosteroid therapy to decrease brain inflammation and edema \[[@B16]\]. The ^18^F-FDG therapy dose can be also be fractionated and corticosteroids can be administered to prevent toxicity to the brain. The dose to the bladder and kidneys can be reduced with a Foley catheter and diuretic administration \[[@B17]\]. These data suggest that ^18^F-FDG therapy can be used safely in ^18^F-FDG-avid malignancies.

With regard to long-term toxicity from positron therapy, it has been shown that after large cumulative doses of ^131^I for metastatic thyroid cancer, the risk of secondary leukemia is 0.4 deaths per 10^4^patient-year-grays \[[@B18]\]. We would expect patients with metastatic breast cancer treated with high doses of FDG to have a similar risk for latent leukemia. Patients who require whole-brain radiation therapy generally do not live long enough to attain a secondary malignancy, and there are no data on this.

One other possible advantage of using ^18^F-FDG as a therapeutic agent in breast cancer is that up to 29% of glucose utilization in the tumor is due to uptake in non-neoplastic cells, mostly macrophages \[[@B19]\]. In a mouse model it has been shown that macrophages contribute to tumor progression and metastasis \[[@B20]\]. Thus, treatment with ^18^F-FDG of metastatic breast cancer with poor prognosis could be particularly suitable because the macrophages are targeted in addition to the tumor cells.

We can envisage the application of other positron-emitters that have longer half-lives and emit higher-energy positrons than those emitted by ^18^F for positron tumor therapy. For example, ^76^Br-labeled bromo-D-glucose \[[@B21]\] could potentially deliver a higher radiation dose to the tumor because ^76^Br has a longer half-life (16.2 hours) than ^18^F and emits positrons with an energy of 3.44 MeV. Other compounds of interest for positron tumor therapy might include ^124^I-labeled iododeoxyuridine (half-life 4.2 days, energy 2.13 MeV), which incorporates into the DNA of cancer cells, and ^64^Cu-pyruvaldehyde bis(N-methylthiosemicarbazone) (half-life 12.7 hours, energy 0.657 MeV) for the treatment of hypoxic tumors.

Conclusion
==========

We have shown, to our knowledge for the first time, that positrons delivered by ^18^F-FDG to mammary tumors in mice cause apoptosis and necrosis of breast cancer cells. The dosimetry of ^18^F-FDG for tumors and normal organs in breast cancer patients suggests that ^18^F-FDG is a candidate for the radiomolecular therapy of refractory breast cancer and other cancers.
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![Coronal FDG-PET images of mice acquired 1 h after i.p. injection of ^18^F-FDG. Slices (2 mm thick) with the highest activity in the tumor were chosen. All mice were lying on their backs with the heads pointing up. Tumors are marked with arrows. Because ^18^F-FDG is normally excreted in the urine, bladder activity is visible in all mice. The highest radioactivity uptake shows as red. **(a)**PyMT mouse with an abdominal mammary tumor. **(b)**PyMT mouse with a thoracic mammary tumor. **(c)**MMTV-*neu*T mouse with a thoracic mammary tumor. **(d)**Tumor-free MMTV *neu*T mouse: no abnormal uptake is seen.](bcr643-1){#F1}

![Apoptosis and necrosis caused by treatment with ^18^F-FDG in mammary tumors in PyMT mice. Apoptotic and necrotic cells were detected with an Apoptag Plus apoptosis detection kit. **(a)**A treated tumor in a 10-week-old mouse has numerous apoptotic cells present (stained brown) in the center of the tumor. **(b)**An untreated tumor in a mouse of the same age has an insignificant number of apoptotic cells. **(c)**Healthy mammary glands of C3H/B6 mice treated with 3 mCi of ^18^F-FDG: no apoptotic or necrotic cells are present. **(d)**A treated tumor in a 22-week-old mouse shows extensive necrotic areas (stained brown--yellow); some apoptotic cells are also seen at the rim of the necrotic area. **(e)**An untreated tumor in a 22-week-old mouse. **(f)**An H&E-stained treated tumor in a 22-week-old mouse: heavy infiltration by leukocytes and a loss of coherence of the tumor cells with breaks in the epithelial sheets are observed. **(g)**An untreated tumor in a mouse of the same age shows solid sheets of tumor cells. Original magnifications: (a--c) × 400; (d--g) × 200.](bcr643-2){#F2}

![^18^F-FDG-PET projection image of a patient with breast cancer metastatic to the right lung. A metastasis to the left lung is also visible. Normal activity is observed in the heart, liver, kidneys, bladder, and bowel. The primary breast cancer had previously been resected, and the residual normal non-lactating breast tissue did not display increased ^18^F-FDG uptake over the background.](bcr643-3){#F3}

###### 

Standardized uptake values (SUVs) for metastatic tumors and normal liver; and tumor to liver ratios (TLRs) in patients with metastatic breast cancer imaged with 3.5 mCi of ^18^F-FDG

                                             SUV         
  --- -------------------------------------- ----- ----- ------
  1   Metastasis to sub-carinal lymph node   5.3   2.8   1.89
  2   Metastasis to the left axilla          7.4   2.3   3.36
  3   Liver metastasis                       5.8   2.6   2.23
  4   Metastasis to the right axilla         5.3   2.1   2.52
  5   Right lung metastasis                  9.9   2.7   3.67

SUVs were calculated for all regions of interest by the formula SUV = (activity in tissue \[mCi/g\] divided by (injected activity \[mCi\]/body weight \[g\]). TLRs were calculated by the formula TLR = SUV of tumor divided by SUV of liver.
